FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2916251350> ?p ?o ?g. }

• W2916251350 abstract "Currently there are no disease-modifying treatments for Parkinson's disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas. One of the leading genetic risk factors for Parkinson's disease is being a carrier in the gene for β-Glucocerebrosidase (GCase; gene name GBA1). Studies in cell culture and animal models have shown that raising the levels of GCase can decrease levels of α-synuclein. Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD. The aims of this trial are to determine if Ambroxol is safe and well-tolerated by individuals with PDD and if Ambroxol affects cognitive, biochemical, and neuroimaging measures.This is a phase II, single-centre, double-blind, randomized placebo-controlled trial involving 75 individuals with mild to moderate PDD. Participants will be randomized into Ambroxol high-dose (1050 mg/day), low-dose (525 mg/day), or placebo treatment arms. Assessments will be undertaken at baseline, 6-months, and 12-months follow up times. Primary outcome measures will be the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) and the ADCS Clinician's Global Impression of Change (CGIC). Secondary measures will include the Parkinson's disease Cognitive Rating Scale, Clinical Dementia Rating, Trail Making Test, Stroop Test, Unified Parkinson's disease Rating Scale, Purdue Pegboard, Timed Up and Go, and gait kinematics. Markers of neurodegeneration will include MRI and CSF measures. Pharmacokinetics and pharmacodynamics of Ambroxol will be examined through plasma levels during dose titration phase and evaluation of GCase activity in lymphocytes.If found effective and safe, Ambroxol will be one of the first disease-modifying treatments for PDD.ClinicalTrials.gov NCT02914366, 26 Sep 2016/retrospectively registered." @default.
• W2916251350 created "2019-03-02" @default.
• W2916251350 creator A5011579867 @default.
• W2916251350 creator A5012679822 @default.
• W2916251350 creator A5015053754 @default.
• W2916251350 creator A5028224518 @default.
• W2916251350 creator A5035358062 @default.
• W2916251350 creator A5037427363 @default.
• W2916251350 creator A5038290862 @default.
• W2916251350 creator A5038715480 @default.
• W2916251350 creator A5053648218 @default.
• W2916251350 creator A5061367519 @default.
• W2916251350 creator A5065709416 @default.
• W2916251350 creator A5067317602 @default.
• W2916251350 creator A5069444754 @default.
• W2916251350 creator A5072242679 @default.
• W2916251350 creator A5075392187 @default.
• W2916251350 creator A5076675090 @default.
• W2916251350 creator A5077429656 @default.
• W2916251350 creator A5079362725 @default.
• W2916251350 date "2019-02-09" @default.
• W2916251350 modified "2023-10-14" @default.
• W2916251350 title "Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial" @default.
• W2916251350 cites W1164896577 @default.
• W2916251350 cites W1593930369 @default.
• W2916251350 cites W1672024307 @default.
• W2916251350 cites W1847168837 @default.
• W2916251350 cites W1953027527 @default.
• W2916251350 cites W1971351343 @default.
• W2916251350 cites W1974704788 @default.
• W2916251350 cites W1979395048 @default.
• W2916251350 cites W1982224533 @default.
• W2916251350 cites W1983182638 @default.
• W2916251350 cites W1984769949 @default.
• W2916251350 cites W1990974805 @default.
• W2916251350 cites W1991952617 @default.
• W2916251350 cites W1995412542 @default.
• W2916251350 cites W1996637092 @default.
• W2916251350 cites W1997811592 @default.
• W2916251350 cites W1997922550 @default.
• W2916251350 cites W1999385317 @default.
• W2916251350 cites W2000216201 @default.
• W2916251350 cites W2004580493 @default.
• W2916251350 cites W2005023775 @default.
• W2916251350 cites W2005532083 @default.
• W2916251350 cites W2008854521 @default.
• W2916251350 cites W2020167843 @default.
• W2916251350 cites W2031365272 @default.
• W2916251350 cites W2048878685 @default.
• W2916251350 cites W2054729559 @default.
• W2916251350 cites W2057979657 @default.
• W2916251350 cites W2058161128 @default.
• W2916251350 cites W2062301023 @default.
• W2916251350 cites W2064963539 @default.
• W2916251350 cites W2072331737 @default.
• W2916251350 cites W2077633683 @default.
• W2916251350 cites W2079896325 @default.
• W2916251350 cites W2083220625 @default.
• W2916251350 cites W2083300726 @default.
• W2916251350 cites W2088791759 @default.
• W2916251350 cites W2099131241 @default.
• W2916251350 cites W2111963393 @default.
• W2916251350 cites W2112519660 @default.
• W2916251350 cites W2115455636 @default.
• W2916251350 cites W2117906353 @default.
• W2916251350 cites W2134369114 @default.
• W2916251350 cites W2140978740 @default.
• W2916251350 cites W2141042831 @default.
• W2916251350 cites W2143991193 @default.
• W2916251350 cites W2144140825 @default.
• W2916251350 cites W2148080316 @default.
• W2916251350 cites W2152727843 @default.
• W2916251350 cites W2152884293 @default.
• W2916251350 cites W2155558741 @default.
• W2916251350 cites W2162310837 @default.
• W2916251350 cites W2165758561 @default.
• W2916251350 cites W2166211493 @default.
• W2916251350 cites W2167311298 @default.
• W2916251350 cites W2168784140 @default.
• W2916251350 cites W2283082484 @default.
• W2916251350 cites W2553724719 @default.
• W2916251350 cites W2588436274 @default.
• W2916251350 cites W2592033002 @default.
• W2916251350 cites W2749718288 @default.
• W2916251350 doi "https://doi.org/10.1186/s12883-019-1252-3" @default.
• W2916251350 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6368728" @default.
• W2916251350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30738426" @default.
• W2916251350 hasPublicationYear "2019" @default.
• W2916251350 type Work @default.
• W2916251350 sameAs 2916251350 @default.
• W2916251350 citedByCount "84" @default.
• W2916251350 countsByYear W29162513502019 @default.
• W2916251350 countsByYear W29162513502020 @default.
• W2916251350 countsByYear W29162513502021 @default.
• W2916251350 countsByYear W29162513502022 @default.
• W2916251350 countsByYear W29162513502023 @default.
• W2916251350 crossrefType "journal-article" @default.
• W2916251350 hasAuthorship W2916251350A5011579867 @default.
• W2916251350 hasAuthorship W2916251350A5012679822 @default.
• W2916251350 hasAuthorship W2916251350A5015053754 @default.

• next